G01N33/56966

IDENTIFICATION OF SUBPOPULATIONS OF CARDIOMYOCYTES
20200248145 · 2020-08-06 ·

Disclosed are subpopulations of mammalian stem cell- or mammalian progenitor cell-derived cardiomyocytes. The subpopulations of cardiomyocytes contain a portion of a population of mammalian stem cell- or mammalian progenitor cell-derived cardiomyocytes. The subpopulations of cardiomyocytes can be CD36.sup.+ subpopulations or CD36.sup. subpopulations. Disclosed are methods of isolating and of using the subpopulations of cardiomyocytes, particularly in cardiac disease modeling, drug screening, cardiotoxicity testing, and cardiac regeneration/repair.

BODILY PROCESSING OF ACTIVITY SENSORS

The invention provides methods and compositions that use a process in the body to deliver an active form of the activity sensor to a target site within the body. The activity sensors, which release detectable reporters when acted on by certain enzymes within the body, are provided as pro-analytes. Processes within the body deliver the activity sensors in active form to a target site of interest. For example, enzymes or a chemical environment within the body may cleave blocking groups from the activity sensors, or the body's tissues and organs may collect the activity sensors at the target site based on size or composition of the activity sensors.

Method for producing renal progenitor cells

A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The disclosed method may include, for example, the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(), CD55(), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326().

Methods for Enriching Pluripotent Stem Cell-Derived Cardiomyocyte Progenitor Cells and Cardiomyocyte Cells based on SIRPA Expression
20200239848 · 2020-07-30 ·

The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.

ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
20200239557 · 2020-07-30 ·

The present invention provides anti-C1q antibodies and methods of using the same.

FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY
20200237936 · 2020-07-30 ·

The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor.

Methods of reducing excitotoxicity-induced retinal ganglionic neuron degeneration by an orthodenticle HOMOLOG2 (OTX2) homeoprotein

The invention relates to the use of a homeoprotein of the bicoid family, in particular of the Otx family, for enhancing the survival of cultivated retinal ganglion neurones, and for preventing or treating ganglion neuron degeneration particularly occurring in glaucoma.

Microdroplet based bioassay platform

Platform technology involving aqueous microdroplet reaction vessels created, arrayed, and characterized by imaging microscopy in a microfluidic device are applied to a wide variety of bioassays involving the detection and phenotypic characterization of single cells. The bioassays include the rapid and automated detection of microbial pathogens and their antibiotic sensitivity from patient samples as well as the characterization of immune responses using a patient's own cells, including the killing of tumor cells.

Methods for assaying cellular binding interactions

There are provided methods, and devices for assaying for a binding interaction between a protein, such as a monoclonal antibody, produced by a cell, and a biomolecule. The method may include retaining the cell within a chamber having an aperture; exposing the protein produced by the cell to a capture substrate, wherein the capture substrate is in fluid communication with the protein produced by the cell and wherein the capture substrate is operable to bind the protein produced by the cell; flowing a fluid volume comprising the biomolecule through the chamber via said aperture, wherein the fluid volume is in fluid communication with the capture substrate; and determining a binding interaction between the protein produced by the cell and the biomolecule.

Methods for Assaying Cellular Binding Interactions

There are provided methods, and devices for assaying for a binding interaction between a protein, such as a monoclonal antibody, produced by a cell, and a biomolecule. The method may include retaining the cell within a chamber having an aperture; exposing the protein produced by the cell to a capture substrate, wherein the capture substrate is in fluid communication with the protein produced by the cell and wherein the capture substrate is operable to bind the protein produced by the cell; flowing a fluid volume comprising the biomolecule through the chamber via said aperture, wherein the fluid volume is in fluid communication with the capture substrate; and determining a binding interaction between the protein produced by the cell and the biomolecule.